{"altmetric_id":15087741,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"reddit":{"unique_users_count":1,"unique_users":["montaukwhaler"],"posts_count":1}},"citation":{"authors":["Asimina Nikolakopoulou","Kon\/nos Tzimopoulos","Haralambos Kerasiotis","Anastasios Kallianos","Catherine Kavvada","Helen Gkartzonika","Emilia Tsarouha","Angeliki Rapti"],"doi":"10.21037\/atm.2016.ab018","endpage":"AB018","first_seen_on":"2016-12-26T17:43:39+00:00","issns":["23055839","23055847"],"issue":"22","journal":"Annals of Translational Medicine","last_mentioned_on":1482560698,"links":["https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5159350\/"],"pubdate":"2016-11-01T00:00:00+00:00","publisher":"AME Publications","startpage":"AB018","title":"AB018. Evaluation of nivolumab as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC)","type":"article","volume":"4"},"altmetric_score":{"score":0.25,"score_history":{"1y":0.25,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":null},"demographics":[],"posts":{"reddit":[{"title":"Evaluation of nivolumab as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC)","url":"http:\/\/www.reddit.com\/r\/nsclc\/comments\/5k1sys\/evaluation_of_nivolumab_as_secondline_treatment\/","license":"public","citation_ids":[15087741],"posted_on":"2016-12-24T06:24:58+00:00","author":{"name":"montaukwhaler","url":"http:\/\/www.reddit.com\/r\/nsclc","id_on_source":"nsclc","followers":1,"subreddit":"non small cell lung cancer"}}]}}